New Zealand markets closed

Progenity, Inc. (PROG)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
1.2400-0.0900 (-6.77%)
At close: 04:00PM EST
1.2700 +0.03 (+2.42%)
After hours: 07:59PM EST

Progenity, Inc.

4330 La Jolla Village Drive
Suite 200
San Diego, CA 92122
United States
855 293 2639

Full-time employees265

Key executives

NameTitlePayExercisedYear born
Mr. Eric d'EsparbesChief Financial Officer602.67kN/A1968
Mr. Damon SilvestryChief Operating Officer461.71kN/A1969
Mr. Aditya P. MohantyCEO & DirectorN/AN/A1967
Eric FoxVP of Fin. & Accounting & TreasurerN/AN/AN/A
Dr. Matthew T. Cooper M.B.A., Ph.D.Chief Scientific OfficerN/AN/A1973
Mr. Troy SeelyeChief Information OfficerN/AN/A1964
Mr. Clarke NeumannSr. VP, Gen. Counsel & Sec.N/AN/A1964
Mr. Hutan Hashemi J.D.Chief Compliance OfficerN/AN/A1979
Mr. George GianakopoulosSr. VP of SalesN/AN/A1962
Ms. Robyn HattonVP of HRN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Progenity, Inc., a biotechnology company, provides develops and commercializes molecular testing products in the United States. It offers Innatal, a noninvasive prenatal screening test offered to women early in pregnancy to screen for chromosome abnormalities, such as down syndrome, trisomy 18, trisomy 13, and sex chromosome disorders through the analysis of cell-free DNA; Preparent that screens for carrier status of hereditary diseases prior to or early in pregnancy; and Riscover, a hereditary cancer screen that analyzes 31 genes associated with inherited risk of 12 types of cancers, including the BRCA1/2 genes for hereditary breast, ovarian, colorectal, endometrial, pancreatic, and other cancer syndromes, as well as for the five genes associated with Lynch syndrome. The company also provides Resura, a noninvasive prenatal test for families at risk for rare single gene disorders; and Preecludia, a preeclampsia rule-out test. In addition, it offers anatomic and molecular pathology tests, and COVID-19 PCR testing services, as well as test products that includes chromosomal microarray for pregnancy loss, which evaluates the genetic cause of miscarriage; maternal serum screening for chromosomal disorders; and preimplantation genetic testing for use with artificial reproductive technologies. Further, the company develops therapeutic solutions for gastrointestinal-related disorders, such as PGN-001, PGN-300, PGN-600, and PGN-OB2. It also owns and operates laboratory. Progenity, Inc. was formerly known as Ascendant MDX, Inc. and changed its name to Progenity, Inc. in November 2013. The company was founded in 2010 and is headquartered in San Diego, California.

Corporate governance

Progenity, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.